$65m Series D supports Pearl's twice-daily COPD combo but more funds needed
This article was originally published in Scrip
Executive Summary
Pearl Therapeutics has raised $65 million in a Series D venture financing round to kick-start its Phase III development plan for the inhaled chronic obstructive pulmonary disease (COPD) drug candidate PT003, but it will need more cash from another private funding deal, a partnership or an initial public offering to complete two planned pivotal trials.